I suspect there are fundamental issues with the FDA process that the company is not disclosing. The management has a serious credibility issue. With the assertion that data verification has been completed and submission will be done in August yet again proven to be false (1 day left for them to prove otherwise), the management must be held to account at the upcoming AGM.
Ann: Influenza B Detection Expected to Impact on Quarter Sales, page-10
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add GSS (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
66.5¢ |
Change
0.020(3.10%) |
Mkt cap ! $150.8M | |||
| Open | High | Low | Value | Volume |
| 65.0¢ | 66.5¢ | 62.5¢ | $165.9K | 260.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 50668 | 62.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 66.5¢ | 19999 | 1 |
View Market Depth
| Last trade - 16.10pm 16/10/2024 (20 minute delay) ? |
| GSS (ASX) Chart |